Abstract:Abstract Therapies targeting oncogene addiction have had a tremendous impact on patient care, but drug resistance continues to be problematic. One method to deal with this challenge entails extending the scope of anti-cancer treatment beyond tumor cells by additionally altering their tumor microenvironment. Understanding how the tumor microenvironment can contribute to the evolution of diverse resistance pathways could aid in the rational design of sequential treatments that enforce pressure towards a more predictable resistance trajectory. Tumor associated macrophages often support neoplastic growth and are frequently the most abundant immune cell found in tumors. Here, we used clinically relevant in vivo Braf-mutant melanoma models and Ccr2-RFP; Cx3cr1-GFP mice to track the long-term changes in tumor cells and macrophages under targeted therapy with Braf/Mek inhibitors. We assessed the dynamic evolution of the macrophage population generated by therapy pressure-induced stress. During the onset of a drug-tolerant persister state, Ccr2+ macrophage infiltration rises, underscoring a prominent role at this point in melanoma evolution for development of drug-resistance. Importantly, we show that a lack of melanoma infiltrating Ccr2+ macrophages delays onset of resistance. In this case, rebounded tumor cells from Ccr2 knockout recipients favor the evolution of cell-extrinsic mediated resistance mechanisms, which can be reversed when these adapted melanoma cells are relocated to a microenvironment with functional Ccr2. Conversely, Ccr2 presence promotes development of cell-intrinsic drug resistance with a stable phenotype in rebounded tumor cells. Overall, this demonstrates that the development of resistance may be manipulated and directed to improve timing and probability of relapse. Citation Format: Dahihm Kim, Luye An, Jiwon Moon, Andrew White. Ccr2+ monocyte derived macrophages influence trajectories of acquired therapy resistance in BRAF-mutant melanoma. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5950.

Macrophage: Hidden Criminal in Therapy Resistance.

Targeting tumor-associated macrophages to reverse antitumor drug resistance

The promising role of tumor-associated macrophages in the treatment of cancer

Macrophages and Metabolic Reprograming in the Tumor Microenvironment

Macrophages as regulators of tumour immunity and immunotherapy

Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy

Macrophages as tools and targets in cancer therapy

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

The portrayal of macrophages as tools and targets: A paradigm shift in cancer management

Role of macrophage in nanomedicine-based disease treatment

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

Role of macrophages in tumor progression and therapy (Review)

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion

Abstract 5950: Ccr2+ monocyte derived macrophages influence trajectories of acquired therapy resistance in BRAF-mutant melanoma

Engineering macrophages and their derivatives: A new hope for antitumor therapy

New insights into the role of macrophages in cancer immunotherapy

Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy

Metabolic reprogramming of macrophages in cancer therapy

Leveraging macrophages for cancer theranostics